Rachel H. Feeney

Rachel H. Feeney

Auto-generated profile, based on publicly available information

Rachel H. Feeney

Department of Molecular Biology, Umeå University, Umeå, Sweden

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHSandra M. Holmberg
Sandra M. Holmberg
RFRachel H. Feeney
Rachel H. Feeney
VPVishnu Prasoodanan P.K.
Vishnu Prasoodanan P.K.
FPFabiola Puértolas-Balint
Fabiola Puértolas-Balint
DSDhirendra K. Singh
Dhirendra K. Singh
BSBjoern O. Schroeder
Bjoern O. Schroeder
Beneficial gut bacteria are indispensable for developing colonic mucus and fully establishing its protective function against intestinal microorganisms. Low-fiber diet consumption alters the gut bacterial configuration and disturbs this microbe-mucus interaction, but the specific bacteria and microbial metabolites responsible for maintaining mucus function remain poorly understood. By using human-to-mouse microbiota transplantation and ex vivo analysis of colonic mucus function, we here show as a proof-of-concept that individuals who increase their daily dietary fiber intake can improve the capacity of their gut microbiota to prevent diet-mediated mucus defects. Mucus growth, a critical feature of intact colonic mucus, correlated with the abundance of the gut commensal Blautia, and supplementation of Blautia coccoides to mice confirmed its mucus-stimulating capacity. Mechanistically, B. coccoides stimulated mucus growth through the production of the short-chain fatty acids propionate and acetate via activation of the short-chain fatty acid receptor Ffar2, which could serve as a new target to restore mucus growth during mucus-associated lifestyle diseases.

13 September 2024 in Science Advances
Verified
Journal Article
Open access
JSJasmin Sawaed
Jasmin Sawaed
LZLilach Zelik
Lilach Zelik
YLYehonatan Levin
Yehonatan Levin
RFRachel Feeney
Rachel Feeney
MNMaria Naama
Maria Naama
SBShai Bel
Shai Bel
Antibiotic use is a risk factor for development of inflammatory bowel diseases (IBDs). IBDs are characterized by a damaged mucus layer, which does not separate the intestinal epithelium from the microbiota. Here, we hypothesized that antibiotics affect the integrity of the mucus barrier, which allows bacterial penetrance and predisposes to intestinal inflammation. We found that antibiotic treatment led to breakdown of the colonic mucus barrier and penetration of bacteria into the mucus layer. Using fecal microbiota transplant, RNA sequencing followed by machine learning, ex vivo mucus secretion measurements, and antibiotic treatment of germ-free mice, we determined that antibiotics induce endoplasmic reticulum stress in the colon that inhibits colonic mucus secretion in a microbiota-independent manner. This antibiotic-induced mucus secretion flaw led to penetration of bacteria into the colonic mucus layer, translocation of microbial antigens into circulation, and exacerbation of ulcerations in a mouse model of IBD. Thus, antibiotic use might predispose to intestinal inflammation by impeding mucus production.

21 July 2024 in Gut Microbes
Verified
Journal Article
Open access
KKKertu Liis Krigul
Kertu Liis Krigul
RFRachel H. Feeney
Rachel H. Feeney
SWSupapit Wongkuna
Supapit Wongkuna
OAOliver Aasmets
Oliver Aasmets
SHSandra M. Holmberg
Sandra M. Holmberg
BSBjoern O. Schroeder
Bjoern O. Schroeder
Recent evidence indicates that repeated antibiotic usage lowers microbial diversity and ultimately changes the gut microbiota community. However, the physiological effects of repeated - but not recent - antibiotic usage on microbiota-mediated mucosal barrier function are largely unknown. By selecting human individuals from the deeply phenotyped Estonian Microbiome Cohort (EstMB), we here utilized human-to-mouse fecal microbiota transplantation to explore long-term impacts of repeated antibiotic use on intestinal mucus function. While a healthy mucus layer protects the intestinal epithelium against infection and inflammation, using ex vivo mucus function analyses of viable colonic tissue explants, we show that microbiota from humans with a history of repeated antibiotic use causes reduced mucus growth rate and increased mucus penetrability compared to healthy controls in the transplanted mice. Moreover, shotgun metagenomic sequencing identified a significantly altered microbiota composition in the antibiotic-shaped microbial community, with known mucus-utilizing bacteria, including Akkermansia muciniphila and Bacteroides fragilis, dominating in the gut. The altered microbiota composition was further characterized by a distinct metabolite profile, which may be caused by differential mucus degradation capacity. Consequently, our proof-of-concept study suggests that long-term antibiotic use in humans can result in an altered microbial community that has reduced capacity to maintain proper mucus function in the gut.

7 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KKKertu Liis Krigul
Kertu Liis Krigul
RFRachel H. Feeney
Rachel H. Feeney
SWSupapit Wongkuna
Supapit Wongkuna
OAOliver Aasmets
Oliver Aasmets
SHSandra M. Holmberg
Sandra M. Holmberg
BSBjoern O. Schroeder
Bjoern O. Schroeder
Recent evidence indicates that repeated antibiotic usage lowers microbial diversity and lastingly changes the gut microbiota community. However, the physiological effects of repeated – but not recent – antibiotic usage on microbiota-mediated mucosal barrier function are largely unknown. By selecting human individuals from the deeply-phenotyped Estonian Microbiome Cohort (EstMB) we here utilised human-to-mouse faecal microbiota transplantation to explore long-term impacts of repeated antibiotic use on intestinal mucus function. While a healthy mucus layer protects the intestinal epithelium against infection and inflammation, using ex-vivo mucus function analyses of viable colonic tissue explants, we show that microbiota from humans with a history of repeated antibiotic use causes reduced mucus growth rate and increased mucus penetrability compared to healthy controls in the transplanted mice. Moreover, shotgun metagenomic sequencing identified a significantly altered microbiota composition in the antibiotic-shaped microbial community, with known mucus-utilising bacteria, including Akkermansia muciniphila and Bacteroides fragilis , dominating in the gut. The altered microbiota composition was further characterised by a distinct metabolite profile, which may be caused by differential mucus degradation capacity. Consequently, our findings suggest that long-term antibiotic use in humans results in an altered microbial community that has reduced capacity to maintain proper mucus function in the gut.

10 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SHSandra M. Holmberg
Sandra M. Holmberg
RFRachel H. Feeney
Rachel H. Feeney
VPVishnu Prasoodanan P.K.
Vishnu Prasoodanan P.K.
FPFabiola Puértolas-Balint
Fabiola Puértolas-Balint
Dhirendra SinghDhirendra Singh
Dhirendra Singh
BSBjoern O. Schroeder
Bjoern O. Schroeder
Beneficial gut bacteria are indispensable for developing colonic mucus and fully establishing its protective function against intestinal microorganisms. Low-fiber diet consumption alters the gut bacterial configuration and disturbs this microbe-mucus interaction, but the specific bacteria and microbial metabolites responsible for maintaining mucus function remain poorly understood. By using human-to-mouse microbiota transplantation and ex vivo analysis of colonic mucus function, our proof-of-concept study demonstrates that individuals who increase their daily dietary fiber intake can improve the capacity of their gut microbiota to prevent diet-mediated mucus defects. Mucus growth, a critical feature of intact colonic mucus, correlated with the abundance of the gut commensal Blautia , and supplementation of Blautia coccoides to mice confirmed its mucus-stimulating capacity. Mechanistically, B. coccoides stimulated mucus growth through the production of the short-chain fatty acids propionate and acetate via activation of the short-chain fatty acid receptor Ffar2, which could serve as a new target to restore mucus growth during mucus-associated lifestyle diseases.